
Roth Capital lowered the firm’s price target on Ovid Therapeutics (OVID) to $5.50 from $8 and keeps a Buy rating on the shares. The company’s Q3 update moves OV329 PPR
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| OVID | Ovid Therapeutics | 2.19 | 1.05 | 91.80% |
| Name | Price | % Change | |
|---|---|---|---|
| $2.19 | +91.80% |

Roth Capital lowered the firm’s price target on Ovid Therapeutics (OVID) to $5.50 from $8 and keeps a Buy rating on the shares. The company’s Q3 update moves OV329 PPR

Ovid Therapeutics (OVID) has disclosed a new risk, in the Brand / Reputation category. Social media and AI-based platforms expose Ovid Therapeutics to evolving compliance, reputational, and information security risks

“The third quarter was focused on execution toward multiple, near-term clinical milestones across our pipeline,” said Meg Alexander, President and Chief Executive Officer. “We anticipate findings from two high potential

08:36 EST Ovid Therapeutics (OVID) files $250M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks

Ovid Therapeutics (OVID) is scheduled to report 3rd quarter earnings on 11/11/2026. Regarding Q3 estimates, Wall Street analysts expect Ovid Therapeutics to post earnings of -$0.09 per share. Revenue expectations

Wolfe Research initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $5 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

Cantor Fitzgerald analyst Imogen Mansfield initiated coverage of Ovid Therapeutics (OVID) with an Overweight rating. The firm’s DCF valuation implies roughly $6/share, over 150% upside, supported by its OV329 oral

Cantor Fitzgerald analyst Imogen Mansfield initiated coverage of Ovid Therapeutics (OVID) with an Overweight rating. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

Meeting to be held in Los Angeles on October 14 hosted by B. Riley. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

As previously reported, Guggenheim initiated coverage of Ovid Therapeutics (OVID) with a Buy rating and $7 price target OV329, the company’s lead asset, is a next-generation GABA-AT inhibitor engineered to
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Initiated | Oct 15, 2026 | ||||
| buy | Initiated | Oct 9, 2026 | ||||
| buy | Reiterated | Oct 8, 2026 | ||||
| buy | Reiterated | Sep 11, 2026 | ||||
| buy | Reiterated | Aug 14, 2026 | ||||
| buy | Reiterated | Aug 14, 2026 | ||||
| buy | Reiterated | Aug 13, 2026 | ||||
| buy | Reiterated | Aug 13, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 15, 2027TBA | $441.63M | $-0.10 | $72.00K | 0.19 | -13.29 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.